Last reviewed · How we verify
Pemetrexed+Cisplatin or Carboplatin
Pemetrexed inhibits multiple folate-dependent enzymes involved in nucleotide synthesis, while cisplatin or carboplatin cross-link DNA, together disrupting cancer cell replication and survival.
Pemetrexed inhibits multiple folate-dependent enzymes involved in nucleotide synthesis, while cisplatin or carboplatin cross-link DNA, together disrupting cancer cell replication and survival. Used for Non-small cell lung cancer (NSCLC), including advanced or metastatic disease, Mesothelioma, Other solid tumors (phase 3 investigational).
At a glance
| Generic name | Pemetrexed+Cisplatin or Carboplatin |
|---|---|
| Sponsor | Sichuan Baili Pharmaceutical Co., Ltd. |
| Drug class | Antifolate antimetabolite + platinum-based chemotherapy combination |
| Target | Thymidylate synthase, dihydrofolate reductase, glycinamide ribonucleotide formyltransferase; DNA (platinum agents) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Pemetrexed is a multitargeted antifolate that inhibits thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase, blocking purine and pyrimidine synthesis. Cisplatin and carboplatin are platinum-based alkylating agents that form DNA adducts and cross-links, preventing DNA replication and transcription. The combination provides synergistic cytotoxic activity against rapidly dividing cancer cells.
Approved indications
- Non-small cell lung cancer (NSCLC), including advanced or metastatic disease
- Mesothelioma
- Other solid tumors (phase 3 investigational)
Common side effects
- Myelosuppression (neutropenia, anemia, thrombocytopenia)
- Nausea and vomiting
- Mucositis
- Nephrotoxicity (cisplatin)
- Peripheral neuropathy
- Fatigue
- Diarrhea
Key clinical trials
- Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer (PHASE2)
- Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin (PHASE1, PHASE2)
- A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180) [MK-3475A] In Advanced Solid Tumors (MK-3475A-C18) (PHASE1)
- A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors (PHASE1)
- A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC (PHASE3)
- Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer (PHASE3)
- A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) (PHASE3)
- Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: